Recent 8-K filings for ATNM

• June 18, 2026, 5:00 PM ET other material materiality 0.65 negative item 8.01

  Actinium submits NYSE American compliance plan after equity deficiency notice

  Received NYSE American deficiency notice on May 27, 2026, for Section 1003(a)(ii): equity below required $4M.

• May 29, 2026, 5:10 PM ET regulatory materiality 0.75 negative item 3.01item 7.01item 9.01 ◈ Listing & Compliance Notices

  Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

  Stockholders' equity $2.3M as of March 31, 2026, below NYSE American's $4M minimum; net losses in last 5 fiscal years.

• August 5, 2024, 7:59 PM ET regulatory materiality 0.90 negative item 7.01item 9.01

  FDA requires additional Phase 3 trial for Iomab-B; SIERRA alone not adequate for BLA filing

  SIERRA met primary endpoint (dCR) with p<0.0001, but FDA now demands overall survival benefit in randomized head-to-head trial.

• February 21, 2023, 6:59 PM ET other material materiality 0.90 positive item 7.01item 9.01

  Actinium announces positive Phase 3 SIERRA trial results for Iomab-B in r/r AML

  Iomab-B met primary endpoint: 22% durable CR vs 0% control (p<0.0001).

• October 31, 2022, 7:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  Actinium's Iomab-B meets primary endpoint in Phase 3 SIERRA AML trial (p<0.0001)

  Phase 3 SIERRA trial of Iomab-B in AML patients 55+ with active relapsed/refractory disease met primary endpoint of durable complete remission (dCR) at 6 months with p<0.0001.

• April 13, 2022, 7:59 PM ET other material materiality 0.75 positive item 1.01

  Actinium licenses Iomab-B to Immedica for $35M upfront plus up to $417M milestones

  Upfront payment of $35 million from Immedica upon signing.

Executive changes

Materiality & sentiment trend

Max materiality 0.90 · Median 0.43 · Most common event other_material

4 positive 3 negative 11 neutral

source · ATNM on sec.gov